Supporting development of mRNA-based therapies by addressing large scale purification challenges
Sponsor
The field of mRNA-based therapies is rapidly evolving. The potential of these therapies has been demonstrated in various fields such as cancer vaccines, tumor immunotherapy and more recently, gene editing and vaccine development. Although the potential of mRNA in therapies seems to be endless, obtaining larger quantities of synthetic mRNA for clinical treatment remains a challenge. The current available methods for mRNA purification are becoming a bottleneck in large-scale manufacturing.
Affinity chromatography, a highly scalable method, has earned its credits in the development of biologics such as the use of Protein A for the purification of therapeutic antibodies and more recently, anti-AAV resins in gene therapy workflows. An effective affinity purification step can help to simplify biomolecule downstream processing, reduce the number of purification steps, and reduce the overall cost of goods in bio-therapeutic manufacturing. To support the development of mRNA-based therapies, we have developed a new affinity resin for the purification and isolation of mRNA from in vitro transcription (IVT) manufacturing processes. This webinar will provide an overview on how this resin can help to maximize efficiency and simplify the mRNA purification process.
Attendees will:
- Understand how affinity chromatography can help to simplify workflows and maximize efficiency of your mRNA purification process
- Learn more about the new Thermo Fisher Scientific™ POROS™ Oligo (dT)25 affinity chromatography resin for the purification of IVT mRNA
SPEAKERS
You might also like
Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME
Pure and simple: understanding LNP analytics for better mRNA-based drugs
Empowering patient care: in-process and quality control solutions for cellular therapies
T cells from beginning to end: optimizing leukopak and drug product cryopreservation
